US 12138301
Compounds including a mutant KRAS sequence and a lipid and uses thereof
granted A61KA61K2039/545A61K2039/55561
Quick answer
US patent 12138301 (Compounds including a mutant KRAS sequence and a lipid and uses thereof) held by Elicio Therapeutics, Inc. expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Elicio Therapeutics, Inc.
- Grant date
- Tue Nov 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 34
- CPC classes
- A61K, A61K2039/545, A61K2039/55561, A61K31/7088, A61K39/001164